Matches in Nanopublications for { <http://www.tkuhn.ch/bel2nanopub/RA4-YV1byk5RVHkomu5kmtAzmu8hdqr2sUF2egho8y2v0#_4> ?p ?o ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- _4 value "Several anticancer therapies target, albeit indirectly, the PI3K/ Akt1 axis and cause inhibition of Akt1 phosphorylation and induction of apoptosis. Examples include herceptin, which inhibits ErbB2 in breast cancer cells; cyclooxygenase-2 (COX-2) inhibitors, which inhibit COX-2 and PDK1 in colon and prostate cancer; gefitnib (Iressa), which targets mutant epidermal growth factor receptor in lung cancer cells; and imatinib mesylate (Gleevec, STI- 571), which targets bcr-abl in leukemia. Conversely, inhibition of anoikis, which contributes to metastasis by trkB or TWIST, involves Akt activation. Given that Akt1 binds to Par-4 in diverse cell types, the action of these therapeutic agents may involve regulation of Par-4 function via Akt1." provenance.
- _4 wasQuotedFrom 16540633 provenance.